Neuroendocrine Regulation of Cytochrome P450 Activity

The activity of cytochrome P450 enzymes in the liver is not solely determined by genetic and local hepatic factors but is profoundly influenced by the central nervous system through neuroendocrine pathways. Neurotransmitter systems—particularly glutamatergic, serotonergic and noradrenergic circuits—modulate hypothalamic and pituitary outputs, altering circulating hormones such as growth hormone, somatostatin and corticosterone. These hormonal fluctuations in turn regulate the expression, protein levels and catalytic activity of key CYP isoforms responsible for drug and endogenous compound metabolism. Such cross‐talk underpins interindividual variability in pharmacokinetics, risks of metabolic drug–drug interactions and the efficacy of psychotropic therapies. A deeper understanding of this bidirectional communication is critical for optimising dosing regimens, anticipating changes in metabolism during disease or ageing and developing personalised treatment strategies that account for neuroendocrine status.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Neuroendocrine Regulation of Cytochrome P450 Activity publication trend

The graph below shows the total number of articles in neuroendocrine regulation of cytochrome p450 activity across all publications each year (not limited to Nature Index journals).

Technical terms

Cytochrome P450 (CYP): A superfamily of haem-containing enzymes responsible for phase I metabolism of drugs and endogenous substrates in the liver and other tissues.

Hypothalamic–pituitary–adrenal (HPA) axis: A major neuroendocrine system involving the hypothalamus and pituitary gland that regulates stress responses and influences corticosteroid secretion.

NMDA receptor: A glutamate‐gated ionotropic receptor in the central nervous system critical for synaptic plasticity and involved in neuroendocrine regulation.

Tryptophan hydroxylase-2 (TPH2): The rate‐limiting enzyme in brain serotonin synthesis; its knockout leads to central serotonin deficiency.

Somatostatin: A hypothalamic peptide that inhibits growth hormone release and modulates neuroendocrine control of liver drug-metabolising enzymes.

References

1. Molecular Mechanisms of the Regulation of Liver Cytochrome P450 by Brain NMDA Receptors and via the Neuroendocrine Pathway—A Significance for New Psychotropic Therapies. International Journal of Molecular Sciences (2023).
2. The effect of brain serotonin deficit (TPH2-KO) on the expression and activity of liver cytochrome P450 enzymes in aging male Dark Agouti rats. Pharmacological Reports (2023).
3. The Selective NMDA Receptor GluN2B Subunit Antagonist CP-101,606 with Antidepressant Properties Modulates Cytochrome P450 Expression in the Liver. Pharmaceutics (2021).
4. The impact of noradrenergic neurotoxin DSP-4 and noradrenaline transporter knockout (NET-KO) on the activity of liver cytochrome P450 3A (CYP3A) in male and female mice. Pharmacological Reports (2022).